Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Small Anim Pract ; 62(8): 704-708, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32935335

RESUMO

This report describes two cases of feline anal sac squamous cell carcinoma. Cat 1 was managed with a multimodal approach combining surgical resection, radiation therapy and systemic therapy (toceranib phosphate; Palladia™) until local recurrence was identified at 236 days postsurgery. At that time, the cat received carboplatin. With the tumour being progressive, the cat was euthanased 552 days post initial surgery. Cat 2 was managed palliatively with a non-steroidal anti-inflammatory (meloxicam) and supportive medications. Unfortunately, with further decline in quality of life following initial diagnosis, the cat was euthanased 28 days later. Squamous cell carcinoma should be considered as a possible differential diagnosis when a cat is presented for investigation of an anal sac mass.


Assuntos
Sacos Anais , Carcinoma de Células Escamosas , Doenças do Gato , Animais , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/veterinária , Doenças do Gato/terapia , Gatos , Diagnóstico Diferencial , Recidiva Local de Neoplasia/veterinária , Qualidade de Vida
2.
J Small Anim Pract ; 60(6): 379-383, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30478900

RESUMO

OBJECTIVES: To assess healing of the canine lower eyelid without anatomical reconstruction. MATERIALS AND METHODS: Retrospective case series of three client-owned dogs with lower eyelid defects. These dogs that underwent debridement of lower eyelid wounds that were left to heal by secondary intention were assessed for anatomical, functional and aesthetic outcomes. RESULTS: Two of the cases had previously undergone tumour resection with a lip-to-lid reconstruction and, following flap failure, developed a full thickness defect. The third dog presented with a traumatic laceration. Each dog lost approximately 70 to 90% of the lower eyelid margin. Two received topical antimicrobial eye drops after debridement, while the third dog required no further treatment. Follow-up periods of 3 years, 15 months and 4 months were available. All owners were satisfied with the cosmetic outcome and provided pictures. One owner reported epiphora but no other ophthalmic complications occurred. CLINICAL SIGNIFICANCE: The result of this small case series supports the notion that not all lower eyelid injuries or tumour resections require anatomical reconstruction. Selected cases can be left to heal by secondary intention with minimal post-operative complications.


Assuntos
Neoplasias Palpebrais/cirurgia , Neoplasias Palpebrais/veterinária , Procedimentos de Cirurgia Plástica/veterinária , Animais , Doenças do Cão/cirurgia , Cães , Pálpebras/cirurgia , Intenção , Estudos Retrospectivos , Resultado do Tratamento
3.
J Vet Intern Med ; 32(1): 107-110, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29131404

RESUMO

BACKGROUND: Sialocele is a collection of saliva that has leaked from a damaged salivary gland or duct and is surrounded by granulation tissue. Surgery is the recognized first-line treatment. Recurrence rate after surgery is 5-14%. Salivary gland tissue is very sensitive to radiation therapy (RT). HYPOTHESIS/OBJECTIVES: Radiation therapy will be useful for the treatment of sialocele. The aims were to characterize response rate and clinical course of dogs with sialocele treated with RT and to determine a starting dose for clinical use. ANIMALS: Eleven dogs with sialocele. METHODS: Retrospective study of response and outcome after RT. RESULTS: All dogs had cervical sialocele. Seven dogs (63.6%) were treated with 3 weekly fractions of 4 Gray (Gy); (total dose, 12 Gy). Three dogs (27.3%) received 4 fractions of 4 Gy (16 Gy) and 1 dog received 5 fractions of 4 Gy (20 Gy) on a Monday-Wednesday-Friday schedule. Six dogs (54%) achieved a complete response (CR), and 5 dogs (45%) achieved a partial response (PR). Three dogs had progression of their sialocele 2, 3, and 9 months after RT; all three had received 12 Gy initially and 2 received 2 additional fractions of 4 Gy (cumulative total dose, 20 Gy) and subsequently achieved remission for >2 years. CONCLUSIONS AND CLINICAL IMPORTANCE: Radiation therapy is useful for the treatment of recurrent sialocele refractory to surgical management and a minimum total dose of 16 or 20 Gy in 4 Gy fractions appears effective.


Assuntos
Doenças do Cão/radioterapia , Doenças das Glândulas Salivares/veterinária , Animais , Estudos de Coortes , Doenças do Cão/cirurgia , Cães , Elétrons/efeitos adversos , Elétrons/uso terapêutico , Feminino , Masculino , Indução de Remissão/métodos , Estudos Retrospectivos , Doenças das Glândulas Salivares/radioterapia , Doenças das Glândulas Salivares/cirurgia , Resultado do Tratamento
4.
Vet Comp Oncol ; 14(4): e135-e145, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25393921

RESUMO

Soft tissue sarcomas (STSs) are locally invasive and surgery with or without radiation therapy is the current standard of care in dogs. Typical protocols for treating incompletely excised STSs involve curative intent radiation with total dose in excess of 50 Gy. Forty-eight dogs with histologically confirmed incomplete or closely excised STSs were treated with a hypofractionated protocol that is typically reserved for palliative radiation therapy (RT) (6-8 Gy/weekly fractions to a total dose of 24-32 Gy). Ten dogs (21%) developed local recurrence, 11 dogs (23%) developed metastasis, and 3 dogs developed both (included in each group). The median progression free survival was 698 days. The local failure-free probability at 1 and 3 years was 81 and 73%. The 1 and 3 years tumour-specific overall survival was 81 and 61%. Long-term local tumour control was achieved in the majority of dogs. This protocol is reasonable to prescribe in older patients or when financial limitations exist.


Assuntos
Doenças do Cão/radioterapia , Sarcoma/veterinária , Neoplasias de Tecidos Moles/veterinária , Animais , Intervalo Livre de Doença , Doenças do Cão/patologia , Cães , Feminino , Masculino , Hipofracionamento da Dose de Radiação , Sarcoma/patologia , Sarcoma/radioterapia , Neoplasias de Tecidos Moles/patologia , Neoplasias de Tecidos Moles/radioterapia
5.
J Vet Intern Med ; 18(2): 219-22, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15058774

RESUMO

Paclitaxel (Taxol) was administered to 25 dogs with histologically confirmed malignant tumors at a dosage of 165 mg/m2 i.v. over 3-6 hours every 3 weeks. Dogs received premedication with antihistimines and corticosteroids to reduce hypersensitivity reactions. However, 64% of the dogs still experienced allergic reactions. Six dogs (24%) had grade 3 or 4 neutropenia, 6 dogs (24%) required hospitalization and 3 dogs (12%) died of sepsis. Five dogs (20%) had a partial response (osteosarcoma [2 dogs] mammary carcinoma [2 dogs] and malignant histiocytosis [1 dog]) for a median duration of 53 days. The overall toxicity was unacceptable at the 165 mg/m2 dose. Therefore, subsequent evaluations of paclitaxel in tumor-bearing dogs should a starting dose of 132 mg/m2 i.v. every 3 weeks.


Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Doenças do Cão/tratamento farmacológico , Neoplasias Mamárias Animais/tratamento farmacológico , Osteossarcoma/veterinária , Paclitaxel/uso terapêutico , Animais , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/efeitos adversos , Diarreia/veterinária , Doenças do Cão/mortalidade , Doenças do Cão/patologia , Cães , Esquema de Medicação , Feminino , Incidência , Infusões Intravenosas/veterinária , Masculino , Neutropenia/veterinária , Osteossarcoma/tratamento farmacológico , Paclitaxel/administração & dosagem , Paclitaxel/efeitos adversos , Registros/veterinária , Estudos Retrospectivos , Análise de Sobrevida , Trombocitopenia/veterinária , Vômito/veterinária , Wisconsin/epidemiologia
6.
Vet Comp Oncol ; 1(4): 207-15, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19379182

RESUMO

Bisphosphonates (BPs) are a class of non-hydrolysable analogues of pyrophosphate that have high affinity for bone mineral and are inhibitors of bone resorption. The in vitro effects of two nitrogen-containing BPs, alendronate (ALE) and zoledronate (ZOL), on growth, induction of apoptosis and effects on cell-cycle distribution in two canine and two human osteosarcoma (OSA) cell lines are investigated here. Both significantly (P < 0.001) reduced cell growth in all cell lines, as assessed by a colorimetric assay with IC(50) values in the range of 7.3-61.4 microM and 7.9-36.3 microM for ALE and ZOL, respectively. Both BPs caused a significant (P < 0.001) dose-dependent increase in the proportion of cells undergoing apoptosis, as assessed both by cell-cycle analysis and by annexin-V binding. Both ALE and ZOL altered the proportion of cells in each phase of the cell cycle, but the extent and proportion was both drug and cell line dependent. These data indicate that the nitrogen-containing BPs have direct anti-tumour activity against canine and human OSA cells.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...